Combs Andrew (CIK 0001825005)

Latest company ownership

Role: Chief Chemistry Officer
Shares held
480,123
Last filed at
Mar 27, 2025
Confidence Score
50.7
2025Q4
Confidence Score History
2020Q3 2025Q4

Recent buy/sell transactions

Exec date Filing date Company Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Mar 25, 2025 Mar 27, 2025 Prelude Therapeutics Inc Chief Chemistry Officer Buy 95.0 +100,000 26.31% $69.3K
Dec 20, 2024 Dec 26, 2024 Prelude Therapeutics Inc Chief Chemistry Officer Buy 95.0 +63,075 20.05% $85.5K
Dec 13, 2021 Dec 15, 2021 Prelude Therapeutics Inc EVP, Head of Chemistry Buy 87.5 +8,000 3.07% $94.9K
Sep 29, 2020 Sep 29, 2020 Prelude Therapeutics Inc EVP, Head of Chemistry Buy 61.3 +1,000 0.39% $19K